Heheh...It definitely isn't my board. I'm only a mod here because we had none and somebody needed to handle the stickies. I really encourage more shareholders to post what they know, but I don't think there are many of them at ihub.
I'm reluctant to post about the science involved because I am not a scientist and I am likely to garble what is in the PR without really adding anything insightful. I am more of a charts and fundamentals trader. As far as those are concerned, the chart looks pretty good lately and the fundamentals are non-existent, but the future looks better.
However, I have been reading the discussions of those who do understand the science, and they seem pretty excited.
In the nutshell: PH-10 is a Phase II therapy for psoriasis. This new data release is great in the sense that it shows that PH-10 was effective even in a 28-day trial (other trials are given 70 days) and even without the light therapy that was believed necessary to activate the drug. This was something nobody was expecting (some even were wondering if PH-10 had been abandoned).
The bad news is not very bad: PH-10 will probably need a new Level II trial for 70 days with light therapy so that the data can be compared with other drugs. This is bad because it will require more time and money, but it is good because the trials will be much cheaper than cancer-drug trials (i.e. PV-10) and shouldn't take very long to accomplish.
The potential for more financing has just become a lot stronger on the basis of this news. Even the potential for a buyout has gone from zero to "not completely zero", a step up. The company's plan all along has been to sell itself off to the highest bidder once it can generate revenue. To reach that point, we need news like we got this week.
So, I think the PH-10 news is bigger than our little .04 pps indicates. I think that this will start an uneven climb (lots of ups and downs) toward .05 this month. Which is a far cry from $3.50, and still leaves a lot of diehard shareholders deep underwater. On the other hand, .05 by January 1 represents a 500% pps increase in 2017, not too shabby.
As for PV-10 in February 2018, I really have no further information. Phase III was estimated to be done by then, but that was awhile ago and we have received no guidance on it. However, there was a PV-10 presentation this year, so they clearly are working on it.
As I said, I am no scientist as this post might illustrate. I am just interested in seeing the trials continue and data come in. While I have had impatient moments of angst this year, overall I am satisfied that the company is active and busy in completing what it started. The board has a financial stake in the company now, and a pps increase is their chief reward. So, they are motivated.
